1. What Is the Nuclear Imaging Agent Market?
The Nuclear Imaging Agent Market encompasses radioactively labelled compounds used in clinical and preclinical nuclear medicine imaging procedures, including positron emission tomography tracers and single photon emission computed tomography agents. They visualise metabolic, physiological, and molecular processes in the living body. The market includes FDG PET imaging agents for oncology glucose metabolism visualisation, cardiac and neurological SPECT tracers, and amyloid and tau PET tracers for Alzheimer's disease imaging. It also includes novel therapeutic radiopharmaceutical-paired diagnostic agents and preclinical PET and SPECT imaging tracers for drug development research. These agents are administered intravenously to patients by nuclear medicine physicians and technologists in hospital nuclear medicine departments and imaging centres for oncology staging, cardiac function assessment, neurological disease diagnosis, and molecular target imaging. Market scope covers radioactively labelled nuclear imaging agents for clinical PET and SPECT diagnostic imaging and preclinical nuclear imaging research. It excludes MRI contrast agents, CT contrast media, ultrasound contrast agents, and therapeutic radiopharmaceuticals not used for diagnostic imaging.
2. Nuclear Imaging Agent Market Size & Forecast
3. Emerging Technologies
- FAPI theranostic imaging agent development is advancing fibroblast activation protein inhibitor PET radiotracers labelled with Ga-68 and F-18 that image FAP-expressing tumour stroma across a wider range of solid tumours than FDG, enabling theranostic. Growing industry adoption of this technology is motivating development.
- Automated Ga-68 labelling cassette systems are advancing compact synthesis modules that automatically produce patient-specific Ga-68-labelled PET imaging doses from commercially available PSMA, DOTATATE, and novel Ga-68 kit precursors. Growing industry adoption of this technology is motivating development.
- Artificial intelligence PET image reconstruction is advancing deep learning reconstruction algorithms that generate diagnostic-quality PET images from shorter acquisition times and reduced administered radiotracer dose, improving patient throughput and reducing radiation exposure in routine. Growing industry adoption of this technology is motivating development.
- Novel precision oncology PET biomarker development is advancing tumour target-specific PET radiotracers including HER2-targeted PET, EGFR mutation PET, and immune checkpoint PD-L1 PET that visualise therapeutic target expression and drug receptor occupancy. Growing industry adoption of this technology is motivating development.
Similar technologies are also transforming adjacent markets. Learn more in our Live Cell Imaging Market.
4. Key Market Opportunity
One of the major opportunities in the Nuclear Imaging Agent Market is the expansion of PSMA PET imaging adoption for prostate cancer staging and recurrence detection in markets outside the United States where PSMA PET reimbursement coverage and imaging infrastructure are still developing. A significant proportion of prostate cancer patients in Europe and Asia Pacific who would benefit from PSMA PET-CT lack access due to limited reimbursement coverage and insufficient Ga-68 production infrastructure outside major academic centres. Growing European and Asia Pacific national reimbursement frameworks for PSMA PET-CT, expanding Ga-68 generator and automated synthesis infrastructure, and increasing oncology centre PSMA PET imaging capability are creating conditions for broad PSMA PET adoption. PSMA PET imaging agent manufacturers that establish commercial distribution networks, obtain national reimbursement approval in European and Asia Pacific markets, and provide oncology centre training for PSMA PET image interpretation are positioned to capture growing international PSMA PET market.
5. Top Companies in the Nuclear Imaging Agent Market
The following organisations hold leading positions in the Nuclear Imaging Agent Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- GE HealthCare (FDG)
- Lantheus Holdings (PSMA PET)
- Eli Lilly (Tauvid)
- PETNET Solutions
- Life Molecular Imaging
- Curium Pharma
- Novartis (Lutathera)
- Blue Earth Diagnostics
- Telix Pharmaceuticals
- ANMI
6. Market Segmentation
The Nuclear Imaging Agent Market is analysed across 5 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Agent Type | FDG PET Agent F-18 FDG Oncology F-18 FDG Cardiac Amyloid PET Agent Florbetapir Amyloid Florbetaben Amyloid Tau PET Agent Flortaucipir Tau PSMA PET Agent Ga-68 PSMA PET F-18 DCFPyL PSMA Cardiac SPECT Agent Tc-99m Sestamibi Cardiac Bone SPECT Agent Tc-99m MDP Bone Scan Novel PET Agent FAPI PET Theranostics Cu-64 Novel PET |
| By Indication | Oncology PET Oncology Staging SPECT Oncology Neurology Amyloid PET AD Tau PET AD Cardiology Myocardial Perfusion SPECT Urology PSMA PET Prostate Infection FDG PET Infection |
| By Modality | PET Agent F-18 PET Ga-68 PET Cu-64 PET SPECT Agent Tc-99m SPECT I-123 SPECT Dual-Mode Theranostic Lu-177 Paired PET Ra-223 Paired SPECT |
| By End User | Hospital Nuclear Medicine Departments Cancer Centre PET Cardiac Imaging Nuclear Standalone PET Imaging Centres Outpatient PET CT Academic Medical Centres Academic Nuclear Medicine Radiopharmacy Networks Centralised Radiopharmacy |
| By Geography | North America Europe Asia Pacific Latin America Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Nuclear Imaging Agent Market trajectory over the forecast period:
FDG PET Technology Remains the Most Widely Deployed Nuclear Imaging Agent for Oncology Staging and Treatment Response Assessment.Oncologists, radiologists, and nuclear medicine physicians staging solid tumours and lymphomas. Assessing chemotherapy response are specifying FDG PET-CT as the standard metabolic imaging modality as fluorodeoxyglucose uptake by metabolically active cancer cells provides whole-body tumour detection with superior sensitivity to anatomical CT alone. GE HealthCare and PETNET Solutions continued commercial distribution of F-18 FDG PET imaging agents to hospital nuclear medicine departments and PET imaging centres in 2024, maintaining FDG as the highest-volume nuclear imaging agent globally.
PSMA PET Technology Is Transforming Prostate Cancer Staging and Biochemical Recurrence Detection.Urologists and radiation oncologists managing prostate cancer patients requiring biochemical recurrence localisation and metastatic staging are adopting PSMA PET-CT with Ga-68 PSMA-11. F-18 DCFPyL tracers that provide superior sensitivity for detecting prostate cancer spread at PSA levels below the threshold for conventional CT and bone scan detection. Lantheus Holdings and ANMI continued commercial development and distribution of Pylarify F-18 DCFPyL and Ga-68 PSMA PET agents in 2024. This grows urology and oncology centre adoption of PSMA PET-CT following FDA approval and growing European and Asia Pacific regulatory authorisation.
Amyloid and Tau PET Technology Is Enabling Pre-Mortem Alzheimer's Disease Pathology Confirmation for Clinical Trials and Diagnosis.Neurologists and dementia specialists evaluating patients with mild cognitive impairment for early Alzheimer's disease diagnosis and clinical trial eligibility are using amyloid PET with florbetapir or florbetaben to detect brain amyloid deposition. Tau PET with flortaucipir to assess neurofibrillary tangle burden before dementia onset. Eli Lilly and GE HealthCare continued commercial development of Tauvid flortaucipir tau PET and Amyvid florbetapir amyloid PET agents in 2024. This grows neurologist adoption following Medicare reimbursement expansion for amyloid PET in appropriate Alzheimer's disease evaluation contexts.
For related market intelligence, see the Cell Imaging Market.
8. Segmental Analysis
By agent type, FDG PET agents dominated the Nuclear Imaging Agent Market in 2025, driven by universal use of F-18 fluorodeoxyglucose as the standard whole-body metabolic PET imaging agent for oncology staging and treatment response. Oncologists and nuclear medicine physicians continue specifying FDG PET-CT as the primary nuclear imaging study for cancer staging as FDG whole-body metabolic imaging provides tumour detection sensitivity exceeding anatomical CT across cancer types. PSMA PET agents are the fastest-growing agent type, driven by growing urological oncology adoption of Ga-68 and F-18 PSMA PET-CT for prostate cancer biochemical recurrence detection and metastatic staging following FDA approval and reimbursement coverage. Urologists and oncologists are increasing PSMA PET-CT prescription as published evidence demonstrates superior sensitivity for prostate cancer recurrence detection at low PSA levels compared with conventional CT and bone scan imaging, changing staging practice.
By indication, oncology dominated the Nuclear Imaging Agent Market in 2025, driven by the large global cancer patient population requiring FDG PET-CT and PSMA PET for initial staging, treatment response assessment, and post-treatment surveillance. Oncology nuclear medicine programmes continue generating the highest nuclear imaging agent demand as FDG PET-CT is a standard staging and response assessment tool across most solid tumour and lymphoma treatment protocols globally. Neurology is the fastest-growing indication, driven by growing amyloid and tau PET imaging adoption for Alzheimer's disease diagnosis and clinical trial patient selection following Medicare reimbursement expansion and new disease-modifying therapy approvals. Neurologists and dementia specialists are increasing amyloid and tau PET prescription as disease-modifying Alzheimer's therapy approvals create clinical need to identify amyloid-positive patients who could benefit from treatment before advanced neurodegeneration.
9. Regional Analysis
Regional demand patterns across the Nuclear Imaging Agent Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Nuclear Imaging Agent Market in 2025, with a market share of 45.0%. The region's leadership reflects the large United States hospital nuclear medicine department base generating the highest global FDG PET and SPECT imaging agent demand, Medicare reimbursement coverage for FDG PET and PSMA PET creating consistent procurement, and the commercial headquarters of major nuclear imaging agent manufacturers including GE HealthCare, Lantheus Holdings, and PETNET Solutions in North America. The large United States oncology programme base performing FDG PET-CT for cancer staging, treatment response assessment, and surveillance generates the highest global F-18 FDG imaging agent dose procurement volume from hospital and outpatient PET imaging centres. Growing United States urological oncology adoption of PSMA PET-CT for prostate cancer staging and biochemical recurrence localisation following FDA approval and Medicare reimbursement is creating consistent new-indication Ga-68 PSMA and F-18 PSMA imaging agent demand at urology and oncology centres.
Highest CAGR Region
Asia Pacific is expected to register the highest CAGR of 9.10% during the forecast period. Growing nuclear medicine imaging infrastructure investment in China, Japan, South Korea, India, and Australia expanding PET-CT scanner installation and FDG imaging agent distribution, increasing PSMA PET adoption for prostate cancer following Asian regulatory approvals, and government oncology programme investment in nuclear medicine imaging are creating demand for nuclear imaging agents. Growing Chinese hospital nuclear medicine department expansion and increasing government cancer programme investment are creating demand for FDG PET imaging agents as PET-CT scanner installation expands at Chinese hospital oncology centres and cancer staging with FDG becomes standard practice. Growing Japanese and South Korean PSMA PET adoption and increasing amyloid and tau PET Alzheimer's imaging agent use are creating new indication demand beyond traditional FDG and SPECT cardiac imaging at Japanese and Korean academic medical centres.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Nuclear Imaging Agent Market was valued at USD 1.22 Bn in 2025 and is projected to reach USD 2.15 Bn by 2034, growing at a CAGR of 6.50% over the 2026–2034 forecast period.
The Nuclear Imaging Agent Market is projected to grow at a CAGR of 6.50% from 2026 to 2034.
North America dominated the Nuclear Imaging Agent Market in 2025, with a market share of 45.0%.
The leading companies in the Nuclear Imaging Agent Market include GE HealthCare (FDG), Lantheus Holdings (PSMA PET), Eli Lilly (Tauvid), PETNET Solutions, Life Molecular Imaging, Curium Pharma, Novartis (Lutathera), Blue Earth Diagnostics, Telix Pharmaceuticals, ANMI.
Fdg pet technology remains the most widely deployed nuclear imaging agent for oncology staging and treatment response assessment.
By agent type, FDG PET agents dominated the Nuclear Imaging Agent Market in 2025, driven by universal use of F-18 fluorodeoxyglucose as the standard whole-body metabolic PET imaging agent for oncology staging and treatment response.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.